Vimarsana.com

Latest Breaking News On - Rajesh malik - Page 1 : vimarsana.com

Revolutionary change in cancer care at AIIMS Bhopal

Revolutionary change in cancer care at AIIMS Bhopal
dailypioneer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypioneer.com Daily Mail and Mail on Sunday newspapers.

Bhopal
Madhya-pradesh
India
Ajai-singh
Aman-kumar
Rajesh-malik
Head-of-the-department-radiology
Interventional-radiology-treatment-center
Interventional-radiology
Associate-professor
Interventional-radiologist
Interventional-oncology

G1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from Needham & Company LLC

G1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from Needham & Company LLC
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Rajesh-malik
Therapeutics-company-profile
Needham-company
Algert-global
Therapeutics-inc
Creative-financial-designs-inc
Acadian-asset-management
Connor-clark-lunn-investment-management-ltd
Get-free-report
Financial-designs
Lunn-investment-management

FY2026 EPS Estimates for G1 Therapeutics, Inc. Reduced by HC Wainwright (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) – Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of G1 Therapeutics in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst E. White now expects that the company will post earnings of $0.72 per share for the […]

United-states
Rajesh-malik
Connor-clark-lunn-investment-management-ltd
Therapeutics-company-profile
Nasdaq
Acadian-asset-management
Therapeutics-inc
Needham-company
Fintrust-capital-advisors
Raymond-james-associates
Free-report
Get-free-report

G1 Therapeutics' (GTHX) "Buy" Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX – Free Report) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $12.00 target price on the stock. Separately, Wedbush reissued an outperform rating and set a $5.00 target price (up previously from $4.00) on shares […]

United-states
Rajesh-malik
Needham-company
Capstone-investment-advisors
Securities-exchange-commission
Jump-financial
Creative-financial-designs-inc
Therapeutics-inc
Therapeutics-company-profile
Free-report
Get-free-report
Exchange-commission

Needham & Company LLC Reiterates "Buy" Rating for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ:GTHX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a research note issued on Wednesday, Benzinga reports. They presently have a $12.00 price target on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 214.96% from […]

United-states
Rajesh-malik
Needham-company
Therapeutics-inc
Jump-financial
Curi-wealth-management
Securities-exchange-commission
Capstone-investment-advisors
Algert-global
Get-free-report
Exchange-commission
Advocates-investment-management

abrdn plc Acquires Shares of 423,869 G1 Therapeutics, Inc. (NASDAQ:GTHX)

abrdn plc bought a new position in G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 423,869 shares of the company’s stock, valued at approximately $1,293,000. abrdn plc owned about 0.82% of G1 Therapeutics at the end […]

United-states
Rajesh-malik
Algert-global
Connor-clark-lunn-investment-management-ltd
Nasdaq
Curi-wealth-management
Therapeutics-inc
Acadian-asset-management
Securities-exchange-commission
Creative-financial-designs-inc
Needham-company
Free-report

abrdn plc Invests $1.29 Million in G1 Therapeutics, Inc. (NASDAQ:GTHX)

abrdn plc acquired a new stake in G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 423,869 shares of the company’s stock, valued at approximately $1,293,000. Several other institutional investors and hedge funds have also recently modified […]

United-states
Rajesh-malik
Needham-company
Acadian-asset-management
Creative-financial-designs-inc
Exchange-commission
Algert-global
Therapeutics-inc
Curi-wealth-management
Nasdaq
Connor-clark-lunn-investment-management-ltd
Free-report

G1 Therapeutics (GTHX) Set to Announce Earnings on Wednesday

G1 Therapeutics (GTHX) Set to Announce Earnings on Wednesday
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Rajesh-malik
Therapeutics-inc
Needham-company
Therapeutics-company-profile
Get-free-report
Trading-down

India Today Group honours Sikh Businesspersons from J&K

India Today Group honours Sikh Businesspersons from J&K
dailyexcelsior.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexcelsior.com Daily Mail and Mail on Sunday newspapers.

India
Jammu
Jammu-and-kashmir
Baramulla
Sahay-ranjeet
Banwarilal-purohit
Anileshs-mahajan
Neetu-bali
Rajesh-malik
Baldev-singh
India-today-group
Peaks-group-of-companies

G1 Therapeutics' (GTHX) "Outperform" Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of G1 Therapeutics (NASDAQ:GTHX – Free Report) in a research report released on Wednesday morning, RTT News reports. Wedbush currently has a $5.00 price objective on the stock, up from their previous price objective of $4.00. Separately, Needham & Company LLC reissued a buy rating and issued a […]

Cambridge
Cambridgeshire
United-kingdom
Rajesh-malik
Johne-jack-jr
Therapeutics-inc
Schonfeld-strategic-advisors
Sigma-securities
Cambridge-investment-research-advisors-inc
Needham-company
Free-report
Investment-research-advisors

vimarsana © 2020. All Rights Reserved.